Shawn P. Williams
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Shawn P. Williams has a total of 370 co-authors. Here are the top co-authors by number of shared publications:
- Chris Jacobsen
Applied Physics Program, Northwestern University, Evanston, IL 60208, USA
16 shared publications Kevin P. Madauss
16 shared publicationsEugene L. Stewart
GlaxoSmithKline, Platform Technology and Science, 5 Moore Drive, Research Triangle Park, North Carolina 27709-3398, United States
10 shared publicationsJ. Kirz
Physics Department, SUNY at Stony Brook, Stony Brook, NY 11794, USA
10 shared publicationsG. Bruce Wisely
9 shared publications- Xiaodong Zhang
Section of Structural and Synthetic Biology, Faculty of Medicine, Imperial College London, London, UK
9 shared publications
Latest Publications
- 29 January 2024
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 100, 117618
Exploration of the P1 residue in 3CL protease inhibitors leading to the discovery of a 2-tetrahydrofuran P1 replacement
- 29 January 2024
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 100, 117618
Exploration of the P1 residue in 3CL protease inhibitors leading to the discovery of a 2-tetrahydrofuran P1 replacement
- 1 January 2022
- Published by Elsevier in Journal of Molecular Biology
- Vol. 434 (2) , 167395
Novel Bent Conformation of CD4 Induced by HIV-1 Inhibitor Indirectly Prevents Productive Viral Attachment
- 1 January 2022
- Published by Elsevier in Journal of Molecular Biology
- Vol. 434 (2) , 167395
Novel Bent Conformation of CD4 Induced by HIV-1 Inhibitor Indirectly Prevents Productive Viral Attachment
- 1 June 2018
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 28 (10) , 1958-1963
An orally available, brain-penetrant CAMKK2 inhibitor reduces food intake in rodent model
- 1 June 2018
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 28 (10) , 1958-1963
An orally available, brain-penetrant CAMKK2 inhibitor reduces food intake in rodent model
- 3 August 2014
- Published by Springer Nature in Nature Chemical Biology
- Vol. 10 (9) , 774-779
A human fatty acid synthase inhibitor binds β-ketoacyl reductase in the keto-substrate site
Human fatty acid synthase (hFAS) is a complex, multifunctional enzyme that is solely responsible for the de novo synthesis of long chain fatty acids. hFAS is highly expressed in a number of cancers, with low expression observed in most normal tissues. Although normal tissues tend to obtain fatty acids from the diet, tumor tissues rely on de novo fatty acid synthesis, making hFAS an attractive metabolic target for the treatment of cancer. We describe here the identification of GSK2194069, a potent and specific inhibitor of the β-ketoacyl reductase (KR) activity of hFAS; the characterization of its enzymatic and cellular mechanism of action; and its inhibition of human tumor cell growth. We also present the design of a new protein construct suitable for crystallography, which resulted in what is to our knowledge the first co-crystal structure of the human KR domain and includes a bound inhibitor.
- 3 August 2014
- Published by Springer Nature in Nature Chemical Biology
- Vol. 10 (9) , 774-779
A human fatty acid synthase inhibitor binds β-ketoacyl reductase in the keto-substrate site
Human fatty acid synthase (hFAS) is a complex, multifunctional enzyme that is solely responsible for the de novo synthesis of long chain fatty acids. hFAS is highly expressed in a number of cancers, with low expression observed in most normal tissues. Although normal tissues tend to obtain fatty acids from the diet, tumor tissues rely on de novo fatty acid synthesis, making hFAS an attractive metabolic target for the treatment of cancer. We describe here the identification of GSK2194069, a potent and specific inhibitor of the β-ketoacyl reductase (KR) activity of hFAS; the characterization of its enzymatic and cellular mechanism of action; and its inhibition of human tumor cell growth. We also present the design of a new protein construct suitable for crystallography, which resulted in what is to our knowledge the first co-crystal structure of the human KR domain and includes a bound inhibitor.
- 29 May 2013
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 57 (5) , 1902-1913
Discovery of a Potent Boronic Acid Derived Inhibitor of the HCV RNA-Dependent RNA Polymerase
A boronic acid moiety was found to be a critical pharmacophore for enhanced in vitro potency against wild-type hepatitis C replicons and known clinical polymorphic and resistant HCV mutant replicons. The synthesis, optimization, and structure–activity relationships associated with inhibition of HCV replication in a subgenomic replication system for a series of non-nucleoside boron-containing HCV RNA-dependent RNA polymerase (NS5B) inhibitors are described. A summary of the discovery of 3 (GSK5852), a molecule which entered clinical trials in subjects infected with HCV in 2011, is included.
- 29 May 2013
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 57 (5) , 1902-1913
Discovery of a Potent Boronic Acid Derived Inhibitor of the HCV RNA-Dependent RNA Polymerase
A boronic acid moiety was found to be a critical pharmacophore for enhanced in vitro potency against wild-type hepatitis C replicons and known clinical polymorphic and resistant HCV mutant replicons. The synthesis, optimization, and structure–activity relationships associated with inhibition of HCV replication in a subgenomic replication system for a series of non-nucleoside boron-containing HCV RNA-dependent RNA polymerase (NS5B) inhibitors are described. A summary of the discovery of 3 (GSK5852), a molecule which entered clinical trials in subjects infected with HCV in 2011, is included.
- 1 October 2011
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (20) , 6154-6160
Conformationally constrained farnesoid X receptor (FXR) agonists: Alternative replacements of the stilbene
- 1 October 2011
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (20) , 6154-6160
Conformationally constrained farnesoid X receptor (FXR) agonists: Alternative replacements of the stilbene
- Open Access
- 10 March 2011
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 54 (7) , 2266-2281
Small Molecule Agonists of the Orphan Nuclear Receptors Steroidogenic Factor-1 (SF-1, NR5A1) and Liver Receptor Homologue-1 (LRH-1, NR5A2)
The crystal structure of LRH-1 ligand binding domain bound to our previously reported agonist 3-(E-oct-4-en-4-yl)-1-phenylamino-2-phenyl-cis-bicyclo[3.3.0]oct-2-ene 5 is described. Two new classes of agonists in which the bridgehead anilino group from our first series was replaced with an alkoxy or 1-ethenyl group were designed, synthesized, and tested for activity in a peptide recruitment assay. Both new classes gave very active compounds, particularly against SF-1. Structure−activity studies led to excellent dual-LRH-1/SF-1 agonists (e.g., RJW100) as well as compounds selective for LRH-1 (RJW101) and SF-1 (RJW102 and RJW103). The series based on 1-ethenyl substitution was acid stable, overcoming a significant drawback of our original bridgehead anilino-substituted series. Initial studies on the regulation of gene expression in human cell lines showed excellent, reproducible activity at endogenous target genes.
- 10 March 2011
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 54 (7) , 2266-2281
Open AccessSmall Molecule Agonists of the Orphan Nuclear Receptors Steroidogenic Factor-1 (SF-1, NR5A1) and Liver Receptor Homologue-1 (LRH-1, NR5A2)
The crystal structure of LRH-1 ligand binding domain bound to our previously reported agonist 3-(E-oct-4-en-4-yl)-1-phenylamino-2-phenyl-cis-bicyclo[3.3.0]oct-2-ene 5 is described. Two new classes of agonists in which the bridgehead anilino group from our first series was replaced with an alkoxy or 1-ethenyl group were designed, synthesized, and tested for activity in a peptide recruitment assay. Both new classes gave very active compounds, particularly against SF-1. Structure−activity studies led to excellent dual-LRH-1/SF-1 agonists (e.g., RJW100) as well as compounds selective for LRH-1 (RJW101) and SF-1 (RJW102 and RJW103). The series based on 1-ethenyl substitution was acid stable, overcoming a significant drawback of our original bridgehead anilino-substituted series. Initial studies on the regulation of gene expression in human cell lines showed excellent, reproducible activity at endogenous target genes.
- 1 February 2011
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (4) , 1206-1213
Conformationally constrained farnesoid X receptor (FXR) agonists: Heteroaryl replacements of the naphthalene
- 1 February 2011
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (4) , 1206-1213
Conformationally constrained farnesoid X receptor (FXR) agonists: Heteroaryl replacements of the naphthalene
- 27 June 2010
- Published by Springer Nature in Nature Structural & Molecular Biology
- Vol. 17 (7) , 808-814
Structure of Rev-erbα bound to N-CoR reveals a unique mechanism of nuclear receptor–co-repressor interaction
The ligand binding domain of nuclear receptor Rev-Erbα recruits corepressor NCoR to regulate target gene expression. Here the crystal structure of Rev-Erbα LBD in complex with a peptide from NCoR ID1 reveals formation of an anti-parallel β-sheet and also shows the corepressor a-helix in a registry different from those previously described in such complexes. Repression of gene transcription by the nuclear receptor Rev-erbα plays an integral role in the core molecular circadian clock. We report the crystal structure of a nuclear receptor–co-repressor (N-CoR) interaction domain 1 (ID1) peptide bound to truncated human Rev-erbα ligand-binding domain (LBD). The ID1 peptide forms an unprecedented antiparallel β-sheet with Rev-erbα, as well as an α-helix similar to that seen in nuclear receptor ID2 crystal structures but out of register by four residues. Comparison with the structure of Rev-erbβ bound to heme indicates that ID1 peptide and heme induce substantially different conformational changes in the LBD. Although heme is involved in Rev-erb repression, the structure suggests that Rev-erbα could also mediate repression via ID1 binding in the absence of heme. The previously uncharacterized secondary structure induced by ID1 peptide binding advances our understanding of nuclear receptor–co-repressor interactions.
- 27 June 2010
- Published by Springer Nature in Nature Structural & Molecular Biology
- Vol. 17 (7) , 808-814
Structure of Rev-erbα bound to N-CoR reveals a unique mechanism of nuclear receptor–co-repressor interaction
The ligand binding domain of nuclear receptor Rev-Erbα recruits corepressor NCoR to regulate target gene expression. Here the crystal structure of Rev-Erbα LBD in complex with a peptide from NCoR ID1 reveals formation of an anti-parallel β-sheet and also shows the corepressor a-helix in a registry different from those previously described in such complexes. Repression of gene transcription by the nuclear receptor Rev-erbα plays an integral role in the core molecular circadian clock. We report the crystal structure of a nuclear receptor–co-repressor (N-CoR) interaction domain 1 (ID1) peptide bound to truncated human Rev-erbα ligand-binding domain (LBD). The ID1 peptide forms an unprecedented antiparallel β-sheet with Rev-erbα, as well as an α-helix similar to that seen in nuclear receptor ID2 crystal structures but out of register by four residues. Comparison with the structure of Rev-erbβ bound to heme indicates that ID1 peptide and heme induce substantially different conformational changes in the LBD. Although heme is involved in Rev-erb repression, the structure suggests that Rev-erbα could also mediate repression via ID1 binding in the absence of heme. The previously uncharacterized secondary structure induced by ID1 peptide binding advances our understanding of nuclear receptor–co-repressor interactions.
- 1 January 2010
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 20 (1) , 371-374
Improving the developability profile of pyrrolidine progesterone receptor partial agonists
- 1 January 2010
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 20 (1) , 371-374
Improving the developability profile of pyrrolidine progesterone receptor partial agonists